RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone

This publication has 23 references indexed in Scilit:

• Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
  American Journal of Kidney Diseases, 1997
• Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro
  Journal of Bone and Mineral Research, 1996
• Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.
  Journal of Clinical Investigation, 1995
• Calcemic response to parathyroid hormone in renal failure: Role of phosphorus and its effect on calcitriol
  Kidney International, 1991
• Calcium Carbonate as a Phosphate Binder in Patients with Chronic Renal Failure Undergoing Dialysis
  New England Journal of Medicine, 1986
• Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis
  The Journal of Pediatrics, 1986
• Role of aluminum hydroxide in raising serum aluminum levels in children undergoing continuous ambulatory peritoneal dialysis
  The Journal of Pediatrics, 1984
• The Use of Deferoxamine in the Management of Aluminum Accumulation in Bone in Patients with Renal Failure
  New England Journal of Medicine, 1984
• The Prevalence of Bone Aluminum Deposition in Renal Osteodystrophy and Its Relation to the Response to Calcitriol Therapy
  New England Journal of Medicine, 1982
• Osteomalacia in Chronic Renal Failure: a Syndrome Previously Reported Only with Maintenance Dialysis
  American Journal of Nephrology, 1982